about
The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeuticsMethodology of clinical trials in lung cancerSunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a 'chemosensitive' relapse: A single-arm phase II study (EORTC-08061).HER-2 Expression in Brain Metastases from Colorectal Cancer and Corresponding Primary Tumors: A Case Cohort Series.Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer.New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response.MET inhibition in lung cancer.A computational index derived from whole-genome copy number analysis is a novel tool for prognosis in early stage lung squamous cell carcinoma.Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: A subset analysis of EORTC 24971 studOutcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study.BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study.Determinants of recovery from amenorrhea in premenopausal breast cancer patients receiving adjuvant chemotherapy in the taxane era.Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: an individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studiThe APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613.INTEGRATED CARE PATHWAYS IN LUNG CANCER: A QUALITY IMPROVEMENT PROJECT.Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064).TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial.Long-term update of the 24954 EORTC phase III trial on larynx preservation.Association of BRCA1, ERCC1, RAP80, PKM2, RRM1, RRM2, TS, TSP1, and TXR1 mRNA expression levels between primary tumors and infiltrated regional lymph nodes in patients with resectable non-small cell lung cancer.Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA)
P50
Q26738677-4E4154D8-A5A1-4B43-8694-E29F7FDAE583Q28071367-E9C39D48-AB18-4A09-9386-38EBC4F82C6DQ33428808-D2C84D4C-4DDF-48F7-A704-03ED6FB28480Q36655951-E52CDCDE-13A1-4C0F-A0F4-D5669C834987Q37356090-D1CAB70F-7CAF-40F1-AC71-8AC66D4E399AQ38245210-DE22992A-0DC5-4842-8932-A9DBFA402D90Q38390016-6E3910BF-BF99-45D5-9928-0694EB3475EFQ38407293-A9A7E9C4-9BC5-480F-B861-DFA5965611DCQ38616101-DD4E64A1-DBB0-4A6E-9BA6-03A8702E5F18Q38708546-3FB107F5-9499-4C24-85AB-852AD572F2F6Q38711537-E090001C-B969-479B-9B9F-4F0EFEC79414Q39867215-FBED5C34-31AD-42B0-A7F3-B430911DC39EQ46064784-F7E9AE88-3304-41E9-A5EF-2A4FCCC1D840Q46935209-94D7BB64-3834-4849-8D08-DF666E980815Q47410558-8BF930AB-0EEF-48F8-AE4C-40D8A6888C95Q48505571-71C95A65-1CFB-4613-9877-B06485554AEBQ49132660-C2779748-8A39-4C62-A7DF-A64343D32B11Q50088569-1B6A5A3A-A67E-4995-AE66-EA152C6DA17DQ53056075-26F31A44-C163-4424-8430-DC93D2966A4EQ54096708-79A28AF6-897C-4CC9-86EE-B94B094A1ADFQ61447554-9A906405-2253-44A2-BD42-97E0F15CA25B
P50
description
researcher ORCID ID = 0000-0001-5534-2874
@en
wetenschapper
@nl
name
Jessica Menis
@ast
Jessica Menis
@en
Jessica Menis
@es
Jessica Menis
@nl
type
label
Jessica Menis
@ast
Jessica Menis
@en
Jessica Menis
@es
Jessica Menis
@nl
prefLabel
Jessica Menis
@ast
Jessica Menis
@en
Jessica Menis
@es
Jessica Menis
@nl
P106
P1153
26648860000
P21
P31
P496
0000-0001-5534-2874